Literature DB >> 16884719

Allosteric activation of antithrombin is independent of charge neutralization or reversal in the heparin binding site.

Jonathan Langdown1, Wendy J Carter, Trevor P Baglin, James A Huntington.   

Abstract

We investigate the hypothesis that heparin activates antithrombin (AT) by relieving electrostatic strain within helix D. Mutation of residues K125 and R129 to either Ala or Glu abrogated heparin binding, but did not activate AT towards inhibition of factors IXa or Xa. However, substitution of residues C-terminal to helix D (R132 and K133) to Ala had minimal effect on heparin affinity but resulted in appreciable activation. We conclude that charge neutralization or reversal in the heparin binding site does not drive the activating conformational change of AT, and that the role of helix D elongation is to stabilize the activated state.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16884719     DOI: 10.1016/j.febslet.2006.07.057

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  3 in total

Review 1.  Molecular mechanisms of antithrombin-heparin regulation of blood clotting proteinases. A paradigm for understanding proteinase regulation by serpin family protein proteinase inhibitors.

Authors:  Steven T Olson; Benjamin Richard; Gonzalo Izaguirre; Sophia Schedin-Weiss; Peter G W Gettins
Journal:  Biochimie       Date:  2010-06-02       Impact factor: 4.079

2.  Kinetic evidence that allosteric activation of antithrombin by heparin is mediated by two sequential conformational changes.

Authors:  Sophia Schedin-Weiss; Benjamin Richard; Steven T Olson
Journal:  Arch Biochem Biophys       Date:  2010-09-15       Impact factor: 4.013

3.  Mutation of the H-helix in antithrombin decreases heparin stimulation of protease inhibition.

Authors:  Patrick R Gonzales; Timothy D Walston; Laureano O Camacho; Dana M Kielar; Frank C Church; Alireza R Rezaie; Scott T Cooper
Journal:  Biochim Biophys Acta       Date:  2007-08-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.